EUVIMEDOpdag EUVIMED
Beobachtungsstudie

Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulizing Crohn's Disease

Runqi Wang, Yanglong Wu, Dongbo Xu, Yeyi Yang, Keyu Qian, Jia Kuang, Xiaohui Wang, Chaoyi Lin, Xin Liu, Guangyu Wu, Dandan Ruan, Binghua Chen and 5 more

Alimentary Pharmacology & Therapeutics · 2026-06 · 63 (11) · 1517-1528

DOI: 10.1111/apt.70600 ↗

At a glance

Beobachtungsstudie in Alimentary Pharmacology & Therapeutics, published online on 2026-03-03. Written by Runqi Wang and 16 co-authors. Institution: Department of Gastrointestinal Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Major MEDLINE topics: Crohn Disease, Leukocyte L1 Antigen Complex, Rectal Fistula, Infliximab. Cited 2 times so far (Crossref); 37 references. Funded by: National Natural Science Foundation of China, Shanghai Baoshan District Key Specialties, Shanghai Baoshan District Health Commission Talents Program.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Accurate assessment of tract‐specific inflammatory activity remains difficult in perianal fistulizing Crohn's disease (pfCD), as current clinical and imaging indices incompletely reflect local activity.

Aims

To evaluate fistula calprotectin (FiCP) as a tract‐specific biomarker, focusing on diagnostic accuracy, associations with histological, clinical, and radiological indices, longitudinal responsiveness, and local infliximab exposure.

Methods

In this single‐center observational study (April 2023–July 2025; n = 105), patients with pfCD provided fistula exudate samples during surgical or outpatient assessment. FiCP concentrations were quantified by ELISA and correlated with histological inflammation, the Perianal Disease Activity Index (PDAI), the MRI‐based modified Van Assche Index (mVAI), and total fistula volume (TFV). Diagnostic performance was analysed using receiver operating characteristic (ROC) curves with DeLong comparison, and treatment responsiveness was evaluated longitudinally using the standardised response mean (SRM). Serum and local infliximab concentrations were measured using ELISA.

Results

FiCP levels were significantly higher in fistulas with severe versus mild histological inflammation ( p = 0.021) and in clinically or radiologically active tracts (both p < 0.001). FiCP correlated with PDAI ( R = 0.61), mVAI ( R = 0.40), and local infliximab concentration ( R = −0.64). FiCP discriminated active from quiescent fistulas (AUC 0.843; 95% CI 0.758–0.928) and retained diagnostic value in patients with normal CDAI scores. FiCP levels declined significantly after therapy and showed greater responsiveness than PDAI and TFV.

Conclusions

FiCP represents a minimally invasive, tract‐specific biomarker that mirrors local inflammatory activity and dynamically tracks treatment response in pfCD. Multicenter validation is warranted to define its clinical utility.

Subjects

MeSH terms (MEDLINE)

Crohn DiseaseLeukocyte L1 Antigen ComplexRectal FistulaInfliximabInflammationHumansFemaleMaleBiomarkersAdultTreatment OutcomeMiddle AgedSeverity of Illness IndexGastrointestinal AgentsROC Curve

Author keywords

Crohn's diseasebiomarkercalprotectindisease activityperianal fistula

Substances

BiomarkersLeukocyte L1 Antigen ComplexInfliximabGastrointestinal Agents

Authors and institutions

  • Department of Gastrointestinal Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Department of General Surgery, Baoshan Branch, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Department of Clinical Laboratory, Baoshan Branch, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Department of Radiology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Department of Dermatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Laboratory of Medicine, Baoshan Branch, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

ORCID profiles: Zhe Cui

Funding

  • National Natural Science Foundation of China
  • Shanghai Baoshan District Key Specialties
  • Shanghai Baoshan District Health Commission Talents Program
  • Shanghai Baoshan District Science and Technology Foundation
  • Ren Ji Hospital Baoshan Branch Cultivated Funding for Clinical Research Innovation

Cite

APA

Wang, R., Wu, Y., Xu, D., Yang, Y., Qian, K., Kuang, J., Wang, X., Lin, C., Liu, X., Wu, G., Ruan, D., Chen, B., Zhang, Y., Li, Y., Wang, Z., Cui, Z., & Cao, D. (2026). Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulizing Crohn's Disease. Alimentary Pharmacology & Therapeutics, 63(11), 1517-1528. https://doi.org/10.1111/apt.70600

Vancouver

Wang R, Wu Y, Xu D, Yang Y, Qian K, Kuang J, et al. Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulizing Crohn's Disease. Alimentary Pharmacology & Therapeutics. 2026;63(11):1517-1528. doi:10.1111/apt.70600

BibTeX
@article{Wang2026,
  author = {Wang, Runqi and Wu, Yanglong and Xu, Dongbo and Yang, Yeyi and Qian, Keyu and Kuang, Jia and Wang, Xiaohui and Lin, Chaoyi and Liu, Xin and Wu, Guangyu and Ruan, Dandan and Chen, Binghua and Zhang, Ye and Li, Yousheng and Wang, Zheng and Cui, Zhe and Cao, Dongxing},
  title = {Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulizing Crohn's Disease},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  volume = {63},
  number = {11},
  pages = {1517--1528},
  doi = {10.1111/apt.70600}
}
Start for free →